Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ovarian Neoplasms × durvalumab × Clear all

Phase

Phase 2 8 Phase 1/2 7 Phase 1 7 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Lung Neoplasms 9 Small Cell Lung Carcinoma 7 Biliary Tract Neoplasms 7 Carcinoma, Hepatocellular 5 Urinary Bladder Neoplasms 4 Liver Neoplasms 4 Carcinoma 4 Small Cell Lung Carcinoma Extensive Disease 2 Recurrence 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasm Metastasis 2 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Urothelial Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Pancoast Syndrome 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Small Cell Lung Carcinoma NSCLC 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1 Locally Advanced or Metastatic EGFR T790M+ NSCLC 1

Interventions

Paclitaxel 67 Carboplatin 56 Bevacizumab 28 liposomal doxorubicin 23 Topotecan 22 Gemcitabine 18 olaparib 16 Cisplatin 13 Doxorubicin 12 Drug Therapy 11 Taxes 10 niraparib 9 Docetaxel 6 Trabectedin 5 CP protocol 5 avelumab 4 atezolizumab 4 Immunoglobulin G 4 Ifosfamide 4 Hyperthermic Intraperitoneal Chemotherapy 4 Disulfides 4 Dexamethasone 4 Cyclophosphamide 4 Chemotherapy, Adjuvant 4 1-dodecylpyridoxal 4 trebananib 3 pembrolizumab 3 fluzoparib 3 dostarlimab 3 cediranib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03737643 2025-01-29

DUO-O

AstraZeneca

Phase 3 Active not recruiting

1,407 enrolled 2 FDA

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡